MetaCap

Ascendis Pharma A/S (ASND) vs Jazz Pharmaceuticals (JAZZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Jazz Pharmaceuticals (JAZZ) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 30.1% versus a gain of 20.1%. Over five years, JAZZ leads with a +85.6% price change compared with +75.7% for ASND. Ascendis Pharma A/S is the larger company by market cap ($16.58 billion vs $14.78 billion), about 1.1 times the size.

On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.6x vs 20.5x for Ascendis Pharma A/S).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASND+20.07%JAZZ+30.14%
+51%+19%-12%
Nov 21, 20251 yearNov 20, 2026
ASND+69.83%JAZZ+79.37%
+108%+23%-61%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASND versus JAZZ key metrics
MetricASNDJAZZ
Share price$252.73$230.26
Market cap$16.58B$14.78B
1-day change-1.26%-2.62%
YTD return+18.52%+35.45%
1-year return+20.07%+30.14%
5-year return+75.73%+85.56%
P/E ratio (TTM)16.6268.12
Forward P/E20.478.61
EPS (TTM)$15.21$3.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.27B
Revenue growth (YoY)—+4.88%
Net income (latest FY)—$-356.15M
Operating margin—-10.08%
Net margin—-8.35%
52-week high$282.15$266.38
52-week low$188.08$156.95
Distance from 52-week high-10.43%-13.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+24.95%+29.20%
Average volume750.65K905.07K
Shares outstanding65.60M64.19M
Employees1,1892,890
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • JAZZ has outperformed ASND by 10.1 percentage points over the past year.
  • Jazz Pharmaceuticals trades at a higher earnings multiple (68.1x vs 16.6x trailing P/E).

About Ascendis Pharma A/S

ASND stock →

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees

About Jazz Pharmaceuticals

JAZZ stock →

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees

ASND vs JAZZ FAQ

Which is bigger, Ascendis Pharma A/S or Jazz Pharmaceuticals?

Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $16.58B compared with $14.78B for Jazz Pharmaceuticals (JAZZ).

Which stock has performed better over the past year, ASND or JAZZ?

JAZZ returned +30.14% over the past 12 months, compared with +20.07% for ASND (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ASND or JAZZ?

ASND has the lower trailing P/E at 16.6, versus 68.1 for JAZZ. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Ascendis Pharma A/S and Jazz Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons